<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378441</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_ATM_105</org_study_id>
    <nct_id>NCT02378441</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor 20mg/Glucophage SR 750mg</brief_title>
  <official_title>A Randomized, Open-labeled, Single-dose, Crossover Design Clinical Trial to Evaluate Pharmacokinetics and Safety of CJ-30056 20/750mg and Co-administration of Lipitor® 20mg and Glucophage SR 750mg in Fed Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate safety and pharmacokinetic properties of the two
      treatments, the administration of CJ-30056 and the co-administration of atorvastatin 20mg and
      metformin SR 750mg, in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the bioequivalence of of CJ-30056 and co-administration of atorvastatin 20mg and
      metformin SR 750mg
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of Atorvastatin and Metformin</measure>
    <time_frame>Up to 32 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve(AUC) of Atorvastatin and Metformin</measure>
    <time_frame>Up to 32 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CJ-30056 20/750mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fixed-dose combination of Atorvastatin 20mg and Metformin SR 750mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20mg and Metformin SR 750mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>co-administration of Atorvastatin 20mg and Metformin SR 750mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20mg and Metformin SR 750mg</intervention_name>
    <description>co-administration of Atorvastatin 20mg and Metformin SR 750mg</description>
    <arm_group_label>CJ-30056 20/750mg</arm_group_label>
    <arm_group_label>Atorvastatin 20mg and Metformin SR 750mg</arm_group_label>
    <other_name>Atorvastatin (Lipitor) and Metformin (Glucophage SR)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-30056 20/750mg</intervention_name>
    <description>fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg</description>
    <arm_group_label>CJ-30056 20/750mg</arm_group_label>
    <arm_group_label>Atorvastatin 20mg and Metformin SR 750mg</arm_group_label>
    <other_name>not yet approved</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing to adhere to protocol requirements and sign a informed consent form

          2. Male volunteers in the age between 19 and 55 years old and have the weight range is
             not exceed ±20% of ideal weight

          3. Subjects with no history of any significant chronic disease

          4. Judged to be in good health on the basis of their vital sign, ECG, physical exam and
             routine laboratory data

        Exclusion Criteria:

          1. Use of barbital inducer or inhibitor medication within the 28 days before dosing

          2. Symptom of an acute illness within 28 days prior to drug administration

          3. History of clinically significant hepatic, renal, gastrointestinal diseases which
             might significantly interfere with ADME

          4. History of surgery except or gastrointestinal diseases which might significantly
             change absorption of medicines

          5. History of clinically significant allergies including drug allergies

          6. History of clinically significant allergies about atorvastatin or metformin

          7. Subjects who have ever or have plan to do intravenous injection of contrast medium
             (intravenous urography, intravenous cholangiography, computed tomography using
             contrast medium) within 28 days prior to drug administration

          8. History of myopathy

          9. Subjects who have genetic problems (galactose intolerance, Lapp lactase deficiency,
             glucose-galactase malabsorption etc.)

         10. Clinical laboratory test values are outside the accepted normal range

               -  AST or ALT &gt;1.25 times to normal range

               -  Total bilirubin &gt;1.5 times to normal range

               -  e-GFR &lt;90 mL/min

         11. History of drug, caffein(caffein &gt; 400mg/day), smoking (cigarette &gt; 10/day) or alcohol
             abuse(alcohol &gt; 30 g/day)or Subjects who have ever drink within 7 days prior to drug
             administration

         12. Special diet known to interfere with the absorption, distribution, metabolism or
             excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior
             to drug administration

         13. Donated blood within 60 days prior to dosing

         14. Participated in a previous clinical trial within 60 days prior to dosing

         15. Use of any other medication, including herbal products, within 10 days before dosing

         16. Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong-lyul Ghim, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University Busanpaik Hospital</affiliation>
  </overall_official>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

